Posted: April 12, 2017 11:11 AM

Lockheed Martin Eyes Military Exoskeleton Market

ORLANDO, Fla. — Eyeing a new generation of industrial and military exoskeletons, Lockheed Martin has licensed the bionic augmentation technology Dermoskeleton from B-Temia Inc., Lockheed said in an April 11 release.

Dermoskeleton is the basis for computer-controlled devices that can increase mobility and load-carrying capacity by counteracting overstress on the lower back and legs. Lockheed Martin’s technology license permits use of B-Temia technology to products for military, industrial, commercial and first-responder applications.

“This technology offers a pathway to increased loadbearing and greater agility for our FORTIS industrial exoskeleton,” said Glenn Kuller, Advanced and Special Programs vice president at Lockheed Martin Missiles and Fire Control. “It can also help to solve existing limitations of powered exoskeletons for our military and first responders. We’re excited about the potential we see here.”

“This agreement confirms our company's technology leadership and value of our work in increasing human mobility in both industrial and defense applications,” said Stéphane Bédard, president and chief executive officer of B-Temia. “Our arrangement with Lockheed Martin provides another avenue for our bionic technology to enhance human performance.”

The FORTIS exoskeleton is an unpowered, lightweight exoskeleton that increases an operator’s strength and endurance by transferring the weight of heavy loads from the operator’s body directly to the ground through a series of joints at the hips, knees and ankles. Originating from Lockheed Martin’s exoskeleton research to assist soldiers in carrying heavy equipment over long distances, the same principles were applied to exoskeleton development for use in industrial settings.



Navy League STEM Expo

Current Issue

Current Issue

Seapower Archives

Seapower Archives

Join Today!

Join Today!
Seapower app